AN2 Therapeutics, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
41AN2 rapeutics's Business Model
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
About AN2 rapeutics
Website: https://www.an2therapeutics.com
CEO (Chief Executive Officer): Mr. Eric E. Easom
IPO date: 2022-03-25
Contact
Country: US
Address: 1800 El Camino Real
City: Menlo Park
State: CA
Phone: 650-331-9090
Zip Code: 94027
Other
CIK: 0001880438
ISIN: US0373261058
CUSIP: 037326105
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
